Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
Carmen Criscitiello, Giulia Viale, Giuseppe Curigliano, Aron Goldhirsch European Institute of Oncology, Milano, Italy Abstract: Alteration of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin signaling pathway is key for the growth and survival of...
Guardado en:
Autores principales: | Criscitiello C, Viale G, Curigliano G, Goldhirsch A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d5bcc36067914069a34e9071aacf3d50 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
por: Criscitiello C, et al.
Publicado: (2018) -
Cryoablation In The Management Of Breast Cancer: Evidence To Date
por: Pusceddu C, et al.
Publicado: (2019) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
por: Irina V. Poddubnaya, et al.
Publicado: (2021) -
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
por: Armaghani AJ, et al.
Publicado: (2020) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021)